MDXG NASDAQ
MiMedx Group, Inc.
1W: +1.7%
1M: +9.1%
3M: -30.2%
YTD: -44.3%
1Y: -49.6%
3Y: -39.7%
5Y: -61.8%
$3.62
+0.01 (+0.28%)
Weekly Expected Move ±9.2%
$3
$3
$4
$4
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (27)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
Is the Options Market Predicting a Spike in MiMedx Group Stock?
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
Mimedx expects $260M-$290M 2026 net sales amid $40M cost cuts and wound care reimbursement disruption
MiMedx (MDXG) Reports Q1 Loss, Tops Revenue Estimates
MIMEDX Announces First Quarter 2026 Operating & Financial Results
MIMEDX Announces First Quarter 2026 Operating & Financial Results
Here are the major earnings after the close Wednesday
Earnings Scheduled For April 29, 2026
Citizens Lowers MiMedx Group, Inc. (MDXG) Valuation to $7 Amid Sluggish Recovery Trends
Earnings Preview: MiMedx (MDXG) Q1 Earnings Expected to Decline
MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29
Catalyst Watch: Tesla talks AI5 chips, Intel reports, and the Warner Bros. deal goes to a vote
10 high-profitability small-cap stocks with lowest YTD performance in 2026
Allspring Global Investments Holdings LLC Acquires 234,958 Shares of MiMedx Group, Inc $MDXG
JPMorgan Chase & Co. Trims Stock Holdings in MiMedx Group, Inc $MDXG
MIMEDX to Sponsor Leading Advanced Wound Care Conferences
MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields
MiMedx targets $340M–$360M 2026 revenue while navigating reimbursement changes and boosting surgical growth
MiMedx (MDXG) Q4 Earnings and Revenues Beat Estimates
MiMedx Group, Inc. (MDXG) Q4 2025 Earnings Call Transcript
MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results
Here are the major earnings after the close Monday
MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25
MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products
MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel